Abstract:Tenoxicam (TNX) is a new non-steroidal anti-inflammatory drug that shows a superior anti-inflammatory effect and has the advantages of a long half-life period, a fast onset of action, a small dose, complete metabolism, and good tolerance. Some compounds often have tautomerism, and different tautomers exist in different crystalline forms. TNX is such a compound and has three tautomers. TNX always exists as the zwitterionic form in cocrystals. When the salt is formed, TNX exists in the enol form, which exhibits two conformations depending on whether a proton is gained or lost. Currently, the crystal structure of the keto form is not in the Cambridge Structural Database (CSD). Based on the analysis of existing crystal structures, we derived a simple rule for what form of TNX exists according to the pKa value of the cocrystal coformer (CCF) and carried out validation tests using three CCFs with different pKa values, including p-aminosalicylic acid (PAS), 3,5-dinitrobenzoic acid (DNB), and 2,6-dihydroxybenzoic acid (DHB). The molecular surface electrostatic potential (MEPS) was combined with the pKa rule to predict the interaction sites. Finally, two new cocrystals (TNX-PAS and TNX-DNB) and one salt (TNX-DHB) of TNX were obtained as expected. The differences between the cocrystals and salt were distinguished by X-ray diffraction, vibration spectra, thermal analysis, and dissolution measurements. To further understand the intermolecular interactions in these cocrystals and salt, the lattice energy and energy decomposition analysis (EDA) were used to explain them from the perspective of energy. The results suggest that the melting point of the CCF determines that of the cocrystal or salt, the solubility of the CCF itself plays an important role, and the improvement of the solubility after salt formation is not necessarily better than that of API or its cocrystals.

The Salt Crystal Structure of Etoricoxib Hydrochloride, C18H16Cl2N2O2S

Crystal Structure of 2-(1-benzyl-3-phenyl-1h-pyrazol-5-yl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole, C25H19N5O3S

Crystal Structure of N-(1-Benzyl-2-Oxoindolin-3-Yl)-N-P-Tolylbenzofuran-2-Carboxamide, C31h24n2o3

Structure analysis and insight into hydrogen bond and van der waals interactions of etoricoxib cocrystals and cocrystal solvate

The Crystal Structure of 2-Phenyl-4,6-bis(prop-2-yn-1-yloxy)-1,3,5-triazine, C15H11N3O2

Crystal structure of 3-(5-((4-(difluoromethoxy)phenyl) sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c ]pyrrol-2(1 H )-yl) oxetane-3-carboxamide, C 17 H 19 F 2 N 3 O 5 S

Crystal Structure of 3-(Tert-butyldiphenylsilyl)-1-(2,6-dichlorophenyl)-2,2-diphenylpropan-1-ol, C37H36Cl2OSi

The Crystal Structure of 1,6-Di-tert-butyl-1,1,3,3,4,4,6,6-octamethyl-2,2,5,5-tetrakis (trimethylsilyl)hexasilane, C28H78Si10

Crystal Structure of N-(5-((3,5-Dimethylisoxazol-4-Yl) Sulfonyl) Quinolin-8-Yl) Benzamide, C21h17n3o4s

The crystal structure of ethyl 2-amino-4-(cyanophenyl)-5-oxo-5,6,7,8-tetrahydro-4 H -chromene-3-carboxylate, C 19 H 18 N 2 O 4

Crystal Structure of 12-Chloro-5,6,7,12-tetra-hydrodibenzo[c,f][1,5]oxastibocine, C14H12ClOSb

Crystal Structure of Ethyl 2-(2-(2-(4-chlorophenyl)-3-methylbutanamido)thiazol-4-yl)acetate, C18h21cln2o3s

Crystal Structure of 2,19-Dithio-9,12,26,29-tetraazanonacyclo- [29.3.1.13,7.16,9.112,15 .114,18.120,24.123,26.129,32]Dotetraconta-1(35),3,5,7(42),14, 16,18(39),20(38),21,23,31,33-Dodecaen-8,13,25,30,36,37,40,41-octone, C36H20N4O8S2

Insight into the Formation of Cocrystal and Salt of Tenoxicam from the Isomer and Conformation

The Crystal Structre of 3-(1-ethenyl-1h-imidazol-3-ium-3-yl)propane-1-sulfonate, C8H12N2O3S

CCDC 1896026: Experimental Crystal Structure Determination

The crystal structure of ethyl 2-amino-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-4 H -chromene-3-carboxylate, C 20 H 22 N 2 O 6

Crystal Structure of 6-Amino-8-(4-isopropylphenyl)-2-methyl-2,3,8,8a-tetrahydroisoquinoline-5,7,7(1h)-tricarbonitrile-ethanol (1/1), C24H29N5O

The Crystal Structure of Oxonium Chlorido-Ethylenediaminetetraactetotin(iv) Hydrate, C10H17ClN2O10Sn

Crystal structure of (8 R ,9 S ,10 R ,13 S ,14 S ,17 S )-17-hydroxy-10,13-dimethyl-17-((4-(2-phenylpropyl)phenyl)ethynyl)-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3 H -cyclopenta[ a ]phenanthren-3-one, C 36 H 42 O 2

Crystal Structure of 3,3,4,4,5,5-Hexafluoro-{1-[2-methyl-5- (4-Formylphenyl)-thien-3-yl]-2-[2-methyl-5-(4-(1,3-dioxolan- 2-Yl)phenyl)-thien-3-yl]}-cyclopent-1-ene, C31H22F6O3S2